3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
21
Lung Neoplasms
10
Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Skin Neoplasms
6
Prostatic Neoplasms
5
Neoplasm Metastasis
5
Melanoma
5
Head and Neck Neoplasms
5
Urinary Bladder Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Merkel Cell
4
Breast Neoplasms
4
Sarcoma
3
Pancreatic Neoplasms
3
Mycosis Fungoides
3
Carcinoma, Squamous Cell
3
Carcinoma, Hepatocellular
3
Carcinoma, Basal Cell
3
Adenocarcinoma
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Rectal Neoplasms
2
Oropharyngeal Neoplasms
2
Mouth Neoplasms
2
Mesothelioma, Malignant
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Interventions
cemiplimab
1
Transdermal Patch
1
Sirolimus
1
Prednisone
1
Everolimus
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cutaneous Squamous Cell Carcinoma
×
cemiplimab
×
Clear all
NCT04339062
2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2
Completed
12 enrolled
13 charts